Cue Biopharma (CUE) Stock Statistics & Valuation Metrics

Cue Biopharma has a market cap or net worth of $136.49M. The enterprise value is $57.31M.

Cue Biopharma has 4,200,343 shares outstanding. The number of shares has decreased by -2.65% in one year.

Cue Biopharma’s return on equity (ROE) is -1.01 and return on invested capital (ROIC) is -86.59%.

The current PE Ratio of Cue Biopharma is ―. Cue Biopharma’s PEG ratio is 0.02.

In the last 12 months, Cue Biopharma had revenue of 27.47M and earned -26.60M in profits. Earnings per share was -8.40.

In the last 12 months, operating cash flow was -24.46M and capital expenditures -148.00K, giving a free cash flow of -24.61M billion.

Cue Biopharma pays an annual dividend of ―, resulting in a dividend yield of ―

Cue Biopharma upcoming earnings date is Aug 18, 2026, TBA (Confirmed).

Cue Biopharma as a current ratio of 2.74, with Debt / Equity ratio of 15.92%

In the past 12 months, Cue Biopharma has paid 500.00K in taxes.

Cue Biopharma EV to EBITDA ratio is -0.27, with an EV/FCF ratio of -0.27.

Cue Biopharma has $16.38M in cash and marketable securities with $3.44M in debt, giving a net cash position of $12.94M billion.

Gross margin is 99.76%, with operating margin of -96.56%, and net profit margin of -96.85%.

The average price target for Cue Biopharma is ―, which is 11.43% higher than the current price. The consensus rating is ―